% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Liu:169710,
      author       = {Z. Liu$^*$ and M. S. Y. Thong$^*$ and D. Doege$^*$ and L.
                      Koch-Gallenkamp$^*$ and H. Bertram and A. Eberle and B.
                      Holleczek and A. Waldmann and S. R. Zeissig and R.
                      Pritzkuleit and H. Brenner$^*$ and V. Arndt$^*$},
      title        = {{P}revalence of benefit finding and posttraumatic growth in
                      long-term cancer survivors: results from a multi-regional
                      population-based survey in {G}ermany.},
      journal      = {British journal of cancer},
      volume       = {125},
      issn         = {1532-1827},
      address      = {Edinburgh},
      publisher    = {Nature Publ. Group},
      reportid     = {DKFZ-2021-01517},
      pages        = {877–883},
      year         = {2021},
      note         = {#EA:C071#LA:C071# / volume 125, pages 877–883 (2021)},
      abstract     = {Cancer studies reported mixed results on benefit finding
                      (BF) and posttraumatic growth (PTG) prevalence and few were
                      focused on long-term survivors.BF and PTG were assessed in a
                      multi-regional population-based study in Germany with 6952
                      breast, colorectal and prostate cancer survivors, using the
                      Benefit Finding Scale and Posttraumatic Growth Inventory. We
                      calculated the age-adjusted prevalence, stratified by
                      demographical and clinical characteristics.Overall, $66.0\%$
                      of cancer survivors indicated moderate-to-high BF, and
                      $20.5\%$ moderate-to-high PTG. Age-adjusted prevalence of BF
                      and PTG differed according to cancer type (breast >
                      colorectal > prostate) and sex (female > male). BF and PTG
                      prevalence were higher in younger than in older respondents;
                      the age-adjusted prevalence was higher in respondents who
                      survived more years after diagnosis. The strength and
                      direction of associations of age-adjusted prevalence with
                      cancer stage, disease recurrence, and time since diagnosis
                      varied according to cancer type and sex.A substantial
                      proportion of long-term cancer survivors reported
                      moderate-to-high BF and PTG. However, the prevalence was
                      lower in older and male cancer survivors, and during the
                      earlier years after cancer diagnosis. Further longitudinal
                      studies on PTG and BF in cancer survivors are warranted to
                      address heterogeneity in survivors' experience after cancer
                      diagnosis.},
      cin          = {C071 / C070 / C120 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)C071-20160331 / I:(DE-He78)C070-20160331 /
                      I:(DE-He78)C120-20160331 / I:(DE-He78)HD01-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:34215852},
      doi          = {10.1038/s41416-021-01473-z},
      url          = {https://inrepo02.dkfz.de/record/169710},
}